Last updated: September 5, 2026
Executive summary: Doravirine is a commercially established but strategically secondary HIV-1 therapy marketed by Merck as Pifeltro and as the fixed-dose combination Delstrigo with lamivudine and tenofovir disoproxil fumarate. Combined sales have remained near $1 billion annually, supported by treatment-experienced patients, tolerability, limited drug-interaction burden relative to older NNRTIs, and Merck’s global HIV infrastructure. Growth is constrained by the shift toward integrase inhibitors, particularly bictegravir- and dolutegravir-based regimens. The principal commercial risk is therapeutic substitution rather than an immediate generic shock. Doravirine is a small molecule, so biosimilar competition does not apply.
Doravirine Market Dynamics, Revenue Trajectory, Patent Protection, and Generic Risk
What is doravirine and how is it positioned in the HIV market?
Doravirine is a once-daily, non-nucleoside reverse transcriptase inhibitor, or NNRTI, developed by Merck & Co. It is approved in two US products:
| Product |
Components |
US FDA approval |
Primary commercial role |
| Pifeltro |
Doravirine 100 mg |
Aug. 30, 2018 |
Two-drug backbone with other antiretrovirals |
| Delstrigo |
Doravirine 100 mg, lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg |
Aug. 30, 2018 |
Complete once-daily three-drug regimen |
The FDA approved doravirine for adults with HIV-1 without prior antiretroviral treatment. The label was later expanded to include adults who were virologically suppressed on a stable regimen and had no history of treatment failure or resistance to doravirine, lamivudine, or tenofovir [1].
Doravirine’s commercial proposition is based on once-daily administration, no requirement for administration with food, and a drug-interaction profile that is less burdensome than efavirenz and several older antiretrovirals. Doravirine does not have the central-nervous-system adverse-effect profile associated with efavirenz and has generally favorable lipid effects in clinical comparisons [1, 2].
Its market position is weaker in first-line treatment because US and international guidelines generally prioritize integrase strand transfer inhibitor, or INSTI, regimens. Biktarvy, Dovato, Triumeq, and dolutegravir-based combinations have established stronger prescribing momentum in treatment-naive patients [3].
How have Pifeltro and Delstrigo sales developed?
Merck reports Pifeltro and Delstrigo together within its HIV portfolio rather than disclosing separate product revenue. Reported sales have been stable at approximately $1 billion per year.
| Fiscal year |
Pifeltro and Delstrigo combined sales |
Commercial interpretation |
| 2021 |
Approximately $1.1 billion |
Mature growth phase |
| 2022 |
Approximately $1.1 billion |
Stable demand |
| 2023 |
Approximately $1.0 billion |
Modest erosion and currency pressure |
| 2024 |
Approximately $1.0 billion |
Mature franchise with continued global contribution |
Sources: Merck annual reports and Form 10-K filings [4-7].
The revenue profile differs from a launch-stage specialty pharmaceutical. Doravirine has not shown the rapid expansion associated with a new high-growth HIV regimen. Its sales have instead reflected:
- Continued use in patients switching from older NNRTI-based therapy.
- Demand for a once-daily regimen with no food requirement.
- Use in patients for whom an INSTI-based regimen is unsuitable or less attractive.
- International sales outside the United States.
- Prescription retention among patients who are virologically suppressed and tolerating therapy.
The franchise is exposed to price and volume pressure as treatment guidelines favor newer regimens and as fixed-dose INSTI combinations gain share. Merck’s revenue trajectory therefore depends more on retention and switching than on large-scale penetration of treatment-naive patients.
What are the main market drivers for doravirine?
Doravirine has several clinically relevant commercial advantages.
Drug-interaction profile
Doravirine is metabolized primarily through CYP3A. The label prohibits use with strong CYP3A inducers such as rifampin, carbamazepine, oxcarbazepine, phenytoin, and St. John’s wort. It does not have the broad interaction restrictions associated with pharmacokinetic boosters such as ritonavir or cobicistat [1].
This profile supports use in patients who require a simple regimen and in some patients who cannot tolerate or manage boosted therapy. The limitation is that doravirine still cannot be used with certain common enzyme-inducing medicines.
Lipid and tolerability profile
Clinical studies comparing doravirine with boosted darunavir and efavirenz reported less lipid deterioration than comparator treatment and fewer neuropsychiatric effects than efavirenz [2, 8]. These attributes support switching in selected virologically suppressed patients.
Treatment-experienced positioning
Doravirine is commercially relevant in patients who are stable but need a regimen change because of adverse effects, drug interactions, pill burden, or lipid concerns. This positioning provides durability even as INSTIs dominate initial therapy.
Global access
Doravirine has regulatory approvals and commercial availability in multiple major markets. Delstrigo’s use of tenofovir disoproxil fumarate, rather than tenofovir alafenamide, may support access in markets where the older formulation has established procurement and generic supply chains. That same formulation limits its appeal where renal and bone safety considerations favor tenofovir alafenamide.
How does doravirine compare with leading HIV regimens?
| Attribute |
Doravirine |
Bictegravir-based regimens |
Dolutegravir-based regimens |
Efavirenz-based regimens |
| Class |
NNRTI |
INSTI |
INSTI |
NNRTI |
| Typical use |
Selected first-line and switch patients |
Preferred first-line and switch treatment |
Preferred first-line and global public-health use |
Declining use |
| Daily dosing |
Once daily |
Once daily |
Once daily, depending on regimen |
Once daily |
| Food requirement |
None for doravirine |
Product-specific |
Product-specific |
Product-specific |
| Booster required |
No |
No |
No |
No |
| Resistance barrier |
Lower than leading INSTIs |
High |
High |
Lower |
| Lipid profile |
Generally favorable |
Generally neutral to favorable |
Generally favorable |
Less favorable |
| Commercial position |
Mature, selective |
Leading |
Leading |
Declining |
The central competitive issue is the higher resistance barrier and guideline preference of INSTI regimens. Doravirine can compete effectively on tolerability and interaction management, but those advantages have not displaced the treatment paradigm established by Biktarvy and dolutegravir-based regimens [3].
When does doravirine lose exclusivity?
Doravirine’s US regulatory exclusivity has already expired. The five-year new chemical entity exclusivity period associated with the 2018 FDA approval ended in 2023, subject to pediatric exclusivity considerations and the specific product approval dates [1, 9].
Regulatory exclusivity and patent exclusivity are separate. Patent protection may continue after NCE exclusivity ends. Doravirine’s patent estate includes composition-of-matter, pharmaceutical composition, and manufacturing-related patent families associated with Merck’s discovery and development program. Public patent records indicate protection extending beyond the initial 2018 approval period, but the applicable expiry dates vary by patent, patent-term adjustment, patent-term extension, and product listing.
The commercially relevant question is not whether one patent has expired. It is whether an ANDA applicant can obtain approval and launch without infringing the patents listed for Pifeltro or Delstrigo.
What is the Orange Book status of Pifeltro and Delstrigo?
Pifeltro and Delstrigo are small-molecule products listed in the FDA Orange Book. The database records approved products, listed patents, and pediatric-exclusivity information. Patent listings can differ between a single-agent product and a fixed-dose combination.
| Product |
Dosage form |
FDA regulatory pathway |
Biosimilar exposure |
Generic pathway |
| Pifeltro |
Oral tablet |
NDA |
Not applicable |
ANDA |
| Delstrigo |
Oral fixed-dose tablet |
NDA |
Not applicable |
ANDA |
A generic applicant may challenge listed patents through a Paragraph IV certification. A Paragraph IV filing would require notice to Merck and could trigger patent litigation under the Hatch-Waxman framework. A 30-month stay may apply if Merck files suit within the statutory period [9, 10].
Publicly available commercial information does not establish a sustained, market-changing Paragraph IV challenge against doravirine. The absence of a visible challenge is not equivalent to the absence of an ANDA or an undisclosed settlement. The principal public risk indicator is a future FDA Orange Book listing of an ANDA applicant or litigation docket involving Pifeltro or Delstrigo patents.
What patent litigation affects doravirine?
Doravirine’s patent risk is driven by four categories:
- Composition-of-matter patents covering doravirine or related chemical entities.
- Pharmaceutical-composition patents covering tablets and fixed-dose combinations.
- Method-of-treatment patents covering HIV treatment with doravirine.
- Manufacturing and process patents covering the active pharmaceutical ingredient or intermediates.
Composition patents normally provide the strongest exclusionary position because they can block products containing the active ingredient regardless of formulation design. Formulation and method-of-use patents may be narrower and more vulnerable to non-infringement or invalidity arguments.
No major publicly documented settlement has established an authorized generic launch date for Pifeltro or Delstrigo. Merck has not publicly disclosed a doravirine settlement comparable to high-profile HIV settlements involving other products. Generic entry timing therefore remains linked to patent expiry, any successful validity challenge, and FDA approval timing.
What generic launch risks exist for doravirine?
The near-term generic risk is moderate rather than immediate.
Pifeltro
A generic version of Pifeltro would need to demonstrate pharmaceutical equivalence and bioequivalence for doravirine 100 mg tablets. The product is technically simpler than Delstrigo because it does not combine three active ingredients.
Delstrigo
Delstrigo presents greater development complexity because an applicant must reproduce a fixed-dose combination containing doravirine, lamivudine, and tenofovir disoproxil fumarate. The individual ingredients are well characterized, but formulation development, bioequivalence, stability, and regulatory documentation remain more demanding than for a single-ingredient tablet.
Commercial launch conditions
A generic entrant would face:
- Established generic versions of lamivudine and tenofovir disoproxil fumarate.
- Strong price competition from low-cost HIV regimens.
- A prescriber market oriented toward INSTIs.
- Potential substitution limits created by payer formularies and treatment guidelines.
- The need to secure access to HIV procurement channels and public-health tenders.
Even after patent clearance, a generic launch may produce gradual rather than immediate erosion if clinicians continue to favor INSTI regimens and if Pifeltro and Delstrigo retain a differentiated switch population.
What manufacturing and intellectual-property barriers protect doravirine?
Doravirine manufacturing is less protected by biological complexity than by pharmaceutical and process know-how. It is a small molecule with conventional oral-tablet delivery. The main barriers are:
- Control of the chemical synthesis route.
- Purity and impurity specifications.
- Reproducible crystalline or solid-state form.
- Scale-up and process validation.
- Bioequivalence of the finished tablet.
- Combination-product formulation for Delstrigo.
- Regulatory documentation for global markets.
These barriers are meaningful but not comparable to the manufacturing barriers for monoclonal antibodies, cell therapies, or long-acting injectable antiretrovirals. Doravirine has no biosimilar risk because biosimilar legislation applies to biologic products, not conventional small molecules.
How strong is the doravirine patent estate?
The estate is commercially useful but aging.
Its strengths are the early composition and chemical-development patents, Merck’s regulatory experience, and the complexity of challenging multiple listed patents across two products. Its weaknesses are the end of five-year NCE exclusivity, the small-molecule nature of the product, the availability of alternative HIV regimens, and the declining strategic importance of NNRTIs in first-line treatment.
Patent strength should be assessed at the claim level. A broad composition claim covering doravirine is more valuable than a narrow tablet or method-of-use claim. The commercial value of later-expiring patents also depends on whether they are listed in the Orange Book and whether an ANDA applicant can design around them.
Which companies are challenging or competing with doravirine?
The principal competitive threat is not one company. It is the HIV regimen portfolios of Gilead Sciences, ViiV Healthcare, and generic manufacturers.
| Company |
Competing products or strategy |
Competitive effect |
| Gilead Sciences |
Biktarvy and other tenofovir-based regimens |
Strong first-line and switch competition |
| ViiV Healthcare |
Dovato, Triumeq, Tivicay, and long-acting Cabenuva |
INSTI dominance and differentiated delivery |
| Generic manufacturers |
Generic lamivudine, tenofovir disoproxil fumarate, efavirenz, and other antiretrovirals |
Lower-cost regimen pressure |
| Merck |
Pifeltro and Delstrigo |
Retention, switching, and global HIV franchise |
No biosimilar company is relevant to doravirine. The competitive landscape is composed of branded small molecules, fixed-dose combinations, long-acting injectables, and generics.
What licensing deals involve doravirine?
Merck retains the primary commercial rights to doravirine and its marketed combinations. Doravirine originated within Merck’s HIV research program. No major external licensing transaction has become a central driver of the product’s commercial profile.
Distribution, co-promotion, or regional commercialization arrangements may exist in individual markets, but they do not alter the core economics: Merck captures the principal branded-product value while absorbing development, regulatory, manufacturing, and commercial costs.
What is the FDA regulatory status of doravirine?
The FDA has approved both Pifeltro and Delstrigo for treatment of HIV-1 infection in adults. The products are prescription oral therapies and are not investigational. Doravirine is not approved as a long-acting injectable, pre-exposure prophylaxis product, or hepatitis therapy [1].
The US guideline environment is commercially important. The Department of Health and Human Services generally recommends INSTI-based regimens for most people beginning treatment, while doravirine remains an option in selected clinical circumstances and for certain switch strategies [3].
What is the likely financial trajectory for doravirine?
The base case is mature-franchise stability followed by gradual erosion.
Base case
Sales remain around the $1 billion level in the near term, with declining treatment-naive share offset by switch patients, international demand, and retention of patients already controlled on doravirine.
Downside case
Revenue declines more rapidly if:
- INSTI prescribing expands further.
- Payers tighten preferred-product placement.
- A generic Pifeltro or Delstrigo launches.
- Merck reduces promotional investment.
- Public-health purchasers favor lower-cost dolutegravir combinations.
Upside case
Meaningful growth would require a new clinical or commercial use, such as stronger guideline placement, a new formulation, an expanded pediatric or special-population indication, or evidence supporting doravirine in patients with specific interaction or tolerability needs. No such catalyst currently matches the scale of the INSTI market shift.
Key Takeaways
- Doravirine is a mature Merck HIV franchise marketed as Pifeltro and Delstrigo.
- Combined annual revenue has remained near $1 billion, but the portfolio is no longer a high-growth launch asset.
- INSTI-based regimens are the primary competitive threat.
- Five-year NCE exclusivity has ended; remaining value depends on patent scope, listed patent expiry, and generic litigation.
- Doravirine is a small molecule and has no biosimilar risk.
- Pifeltro is easier to copy than Delstrigo, which is a three-drug fixed-dose combination.
- Generic entry would likely cause progressive erosion rather than an immediate collapse because prescribing is already concentrated in selected patients.
- The strongest protection is likely associated with active-ingredient and chemical patents, while formulation and method-of-use patents are narrower.
- Merck’s financial exposure is material but manageable within its broader pharmaceutical portfolio.
- The strategic outlook is stable-to-declining, with retention and switching more important than first-line expansion.
FAQs About Doravirine Market and Patent Risk
Is doravirine still used as first-line HIV treatment?
Yes. Doravirine remains an approved first-line option, but US guidelines generally prioritize INSTI-based regimens for most treatment-naive adults.
Is Delstrigo more vulnerable to generic competition than Pifeltro?
Delstrigo has greater formulation complexity, but it also competes against inexpensive generic components. Pifeltro is simpler to reproduce but has a smaller commercial base as a single-agent product.
Does doravirine have pediatric exclusivity?
Pediatric exclusivity depends on FDA qualification and completion of the applicable pediatric studies. Any added exclusivity must be assessed against the FDA approval and Orange Book records for each product.
Can doravirine be used with rifampin?
No. Strong CYP3A inducers, including rifampin, can substantially reduce doravirine exposure and are contraindicated under the US label [1].
Could a generic doravirine launch before all Merck patents expire?
Yes, if an ANDA applicant successfully challenges listed patents, obtains a favorable settlement, or receives approval after a non-infringing design and the relevant exclusivity barriers have ended.
References
-
U.S. Food and Drug Administration. (2024). Pifeltro (doravirine) prescribing information. FDA.
-
Orkin, C., Squires, K. E., Fätkenheuer, G., et al. (2019). Doravirine versus darunavir plus ritonavir in treatment-naive adults with HIV-1: Week 96 results of the DRIVE-FORWARD trial. Clinical Infectious Diseases, 68(4), 535-544.
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
-
Merck & Co., Inc. (2022). 2021 annual report. Merck.
-
Merck & Co., Inc. (2023). 2022 annual report. Merck.
-
Merck & Co., Inc. (2024). 2023 annual report. Merck.
-
Merck & Co., Inc. (2025). 2024 annual report. Merck.
-
Molina, J.-M., Squires, K., Sax, P. E., et al. (2018). Doravirine versus ritonavir-boosted darunavir in treatment-naive adults with HIV-1: Week 48 results of the DRIVE-FORWARD trial. The Lancet HIV, 5(5), e211-e220.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. 21 U.S.C. § 355.
